IL-2 therapy: potential impact of the CD4 cell count at initiation on clinical efficacy--results from the ANRS CO4 cohort | Zendy

Éric Fontas | Zendy; Isabelle Kousignian | Zendy; Christian Pradier | Zendy; Sylvie Abel | Zendy; Christine Durier | Zendy; Laurence Weiss | Zendy; Yves Lévy | Zendy; Dominique Costagliola | Zendy

Open Access

IL-2 therapy: potential impact of the CD4 cell count at initiation on clinical efficacy--results from the ANRS CO4 cohort

Author(s) -

Éric Fontas,

Isabelle Kousignian,

Christian Pradier,

Sylvie Abel,

Christine Durier,

Laurence Weiss,

Yves Lévy,

Dominique Costagliola

Publication year - 2010

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkq296

Subject(s) - medicine , cohort , cohort study , clinical trial , immunology

We investigated why, despite its beneficial effect on the CD4 cell count, IL-2 therapy had no clinical benefit as shown in the ESPRIT and SILCAAT trials. We focused on subgroups of patients defined according to CD4 cell counts at baseline and over time to assess the threshold above which IL-2 therapy was no longer beneficial in a large cohort of HIV-1 infected patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research